Terence Friedlander, MD
The bladder cancer community has generated excitement with 5 monotherapy approvals for PD-1/PD-L1 inhibitors within the last year, including nivolumab (Opdivo), durvalumab (Imfinzi), avelumab (Bavencio), atezolizumab (Tecentriq), and pembrolizumab (Keytruda).
on Genitourinary Cancers. In an interview, he spoke about the targeted therapies emerging in the field, as well as immunotherapy combinations that are travelling through the pipeline.
OncLive: Please summarize the key points of your discussion.
The major focus of my talk was on immunotherapy, because there has been just a number of new agents approved and there is a lot of excitement in the field right now about using these drugs. We discussed why immunotherapy might work, and 1 of the major take-home points is that bladder cancer is very mutated compared with other agents. That has to do with other exposures, including tobacco, environmental, and industrial exposures that cause a lot of damage to the bladder lining and can cause the cancer to form. That presents a lot of targets for both the immune system to see an attack and target for targeted therapy.
... to read the full story